In the third quarter, Chemistry Wealth Management LLC increased its stake in UnitedHealth Group by 59.2%, acquiring an additional 6,022 shares and bringing its total to 16,199 shares. This holding represents 1.1% of the firm’s overall portfolio, making UnitedHealth Group its 18th-largest position. At quarter end, the fund’s investment in the healthcare conglomerate was valued at $5.59 million, reflecting the firm’s conviction in the company’s diversified health benefits and services platforms.

Several large institutions also moved to reshape their exposure to UnitedHealth Group during the year. Norges Bank initiated a new position valued at $3.84 billion, while Berkshire Hathaway allocated $1.57 billion to the stock in the same period. Dodge & Cox more than doubled its ownership, adding 4.73 million shares and growing its holding by 117.7% to a total market value of $2.73 billion. Lone Pine Capital deployed approximately $528 million to establish a fresh stake, and Amundi increased its position by 33.8%, purchasing 1.57 million additional shares for $1.90 billion. Collectively, institutional investors now hold nearly 88% of the outstanding shares.

Research firms have revised their outlooks for UnitedHealth Group, reflecting confidence in the firm’s growth trajectory. Morgan Stanley raised its price target from $325 to $395 and maintained an overweight rating. Royal Bank of Canada increased its target from $286 to $408, continuing to endorse an outperform stance. Goldman Sachs initiated coverage with a buy recommendation and a $406 target, while UBS boosted its objective from $378 to $430, reaffirming a buy rating. Zacks Research upgraded the stock from strong sell to hold. In total, 17 analysts rate the company as a buy, nine as hold and three as sell, with a consensus objective near $386.

UnitedHealth Group reported third-quarter revenue of $113.16 billion, up 12.2% year-over-year, narrowly missing consensus by $30 million. Earnings of $2.92 per share exceeded expectations by $0.05, driving a net margin of 4.04% and a return on equity of 19.23%. The company’s strong cash flows supported a quarterly dividend of $2.21 per share, paid in mid-December, representing an annualized yield of 2.7% and a payout ratio of 46.1%. Management reaffirmed guidance, forecasting full-year earnings per share near $29.54.